{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:32:32Z","timestamp":1794879152400,"version":"4.9.1"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T00:00:00Z","timestamp":1575936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.vaccine.2019.12.011","type":"journal-article","created":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:08:20Z","timestamp":1577146100000},"page":"A118-A126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":82,"special_numbering":"S1","title":["Current and future cholera vaccines"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8958-5644","authenticated-orcid":false,"given":"Hanif","family":"Shaikh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Louis","family":"Excler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.12.011_b0005","doi-asserted-by":"crossref","first-page":"408","DOI":"10.3855\/jidc.410","article-title":"Is cholera disease associated with poverty?","volume":"3","author":"Talavera","year":"2009","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.vaccine.2019.12.011_b0010","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4269\/ajtmh.12-0721","article-title":"Environmental factors influencing epidemic cholera","volume":"89","author":"Jutla","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.12.011_b0015","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40572-017-0132-5","article-title":"Natural Disasters and Cholera Outbreaks: Current Understanding and Future Outlook","volume":"4","author":"Jutla","year":"2017","journal-title":"Curr Environ Health Rep"},{"key":"10.1016\/j.vaccine.2019.12.011_b0020","doi-asserted-by":"crossref","first-page":"e0003832","DOI":"10.1371\/journal.pntd.0003832","article-title":"Updated global burden of cholera in endemic countries","volume":"9","author":"Ali","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0025","first-page":"34","article-title":"Cholera outbreaks","volume":"379","author":"Nair","year":"2014","journal-title":"Curr Top Microbiol Immunol"},{"key":"10.1016\/j.vaccine.2019.12.011_b0030","unstructured":"World Health Organization. Weekly Update Cholera, 06 July 2017. Surveillance, forcasting and Response 2017."},{"key":"10.1016\/j.vaccine.2019.12.011_b0035","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/j.vaccine.2016.03.004","article-title":"Impact of oral cholera vaccines in cholera-endemic countries: A mathematical modeling study","volume":"34","author":"Kim","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0040","doi-asserted-by":"crossref","first-page":"8529","DOI":"10.1073\/pnas.1105807108","article-title":"Vaccines in the time of cholera","volume":"108","author":"Clemens","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2019.12.011_b0045","first-page":"633","article-title":"Changing profile of Vibrio cholerae O1, O139 in Delhi & its periphery (2003\u20132005)","volume":"125","author":"Sharma","year":"2007","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2019.12.011_b0050","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1128\/CMR.8.1.48","article-title":"Cholera","volume":"8","author":"Kaper","year":"1995","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.vaccine.2019.12.011_b0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12941-017-0185-1","article-title":"Pandemics, pathogenicity and changing molecular epidemiology of cholera in the era of global warming","volume":"16","author":"Chowdhury","year":"2017","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.vaccine.2019.12.011_b0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0140-6736(03)15328-7","article-title":"Cholera","volume":"363","author":"Sack","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0065","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.1128\/JCM.40.9.3296-3299.2002","article-title":"New variants of Vibrio cholerae O1 biotype El Tor with attributes of the classical biotype from hospitalized patients with acute diarrhea in Bangladesh","volume":"40","author":"Nair","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2019.12.011_b0070","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1128\/JCM.00799-10","article-title":"Cholera toxin production by the El Tor variant of Vibrio cholerae O1 compared to prototype El Tor and classical biotypes","volume":"48","author":"Ghosh-Banerjee","year":"2010","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.vaccine.2019.12.011_b0075","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3201\/eid1406.080129","article-title":"Vibrio cholerae O1 hybrid El Tor Strains, Asia and Africa","volume":"14","author":"Safa","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0080","unstructured":"SAGE Working Group on Oral Cholera Vaccines, World Health Organization (WHO) Secretariat, Centers for Disease Control and, Prevention. Background Paper on Whole-Cell, Killed, Oral Cholera Vaccines 2017. p. 107."},{"key":"10.1016\/j.vaccine.2019.12.011_b0085","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/0163-4453(93)94398-U","article-title":"Nationwide prevalence of the new epidemic strain of Vibrio cholerae O139 Bengal in India","volume":"27","author":"Garg","year":"1993","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2019.12.011_b0090","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/0140-6736(93)92811-7","article-title":"Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Cholera Working Group, International Centre for Diarrhoeal Diseases Research, Bangladesh","volume":"342","author":"Cholera working group","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0095","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/0264-410X(92)90324-D","article-title":"An oral B subunit: whole cell vaccine against cholera","volume":"10","author":"Holmgren","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0100","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1128\/iai.62.5.2108-2110.1994","article-title":"Vibrio cholerae O139 synonym bengal is closely related to Vibrio cholerae El Tor but has important differences","volume":"62","author":"Johnson","year":"1994","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.12.011_b0105","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.1128\/IAI.73.10.6577-6583.2005","article-title":"Reduction in capsular content and enhanced bacterial susceptibility to serum killing of Vibrio cholerae O139 associated with the 2002 cholera epidemic in Bangladesh","volume":"73","author":"Qadri","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.12.011_b0110","doi-asserted-by":"crossref","first-page":"e0004183","DOI":"10.1371\/journal.pntd.0004183","article-title":"Vibrio cholerae Serogroup O139: Isolation from Cholera patients and asymptomatic household family members in Bangladesh between 2013 and 2014","volume":"9","author":"Chowdhury","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0115","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/infdis\/169.1.230","article-title":"Lack of cross-protection against diarrhea due to Vibrio cholerae O139 (Bengal strain) after oral immunization of rabbits with V. cholerae O1 vaccine strain CVD103-HgR","volume":"169","author":"Albert","year":"1994","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0120","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/0035-9203(79)90119-6","article-title":"Immunity of cholera in man: relative role of antibacterial versus antitoxic immunity","volume":"73","author":"Levine","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2019.12.011_b0125","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1093\/infdis\/jir416","article-title":"Natural cholera infection-derived immunity in an endemic setting","volume":"204","author":"Ali","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0130","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/infdis\/151.2.236","article-title":"Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection","volume":"151","author":"Glass","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0135","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1086\/421275","article-title":"Incomplete correlation of serum vibriocidal antibody titer with protection from Vibrio cholerae infection in urban Bangladesh","volume":"189","author":"Saha","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0140","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1093\/cid\/cis238","article-title":"Nomenclature for immune correlates of protection after vaccination","volume":"54","author":"Plotkin","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0145","series-title":"Cholera and Related Diarrheas, Molecular Aspects of a Global Health Problem 43rd Nobel Symposium, co-sponsored by WHO, Stockholm, August 1978","first-page":"204","article-title":"Field trials of cholera vaccine","author":"Feeley","year":"1980"},{"key":"10.1016\/j.vaccine.2019.12.011_b0150","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/S0140-6736(17)30559-7","article-title":"Cholera","volume":"390","author":"Clemens","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0155","series-title":"Vaccines","first-page":"141","article-title":"11 \u2013 Cholera vaccines A2 \u2013 Plotkin, Stanley A","author":"Clemens","year":"2013"},{"key":"10.1016\/j.vaccine.2019.12.011_b0160","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/infdis\/158.2.372","article-title":"Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial","volume":"158","author":"Clemens","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0165","first-page":"117","article-title":"Cholera vaccines: WHO position paper","volume":"85","author":"World Health Organization","year":"2010","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2019.12.011_b0170","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/infdis\/155.1.79","article-title":"B subunit-whole cell and whole cell-only oral vaccines against cholera: studies on reactogenicity and immunogenicity","volume":"155","author":"Clemens","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0175","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1086\/315462","article-title":"Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in peru","volume":"181","author":"Taylor","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0180","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0140-6736(96)06107-7","article-title":"Field trial of a locally produced, killed, oral cholera vaccine in Vietnam","volume":"349","author":"Trach","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0185","first-page":"2","article-title":"Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam","volume":"80","author":"Trach","year":"2002","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.12.011_b0190","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.vaccine.2006.09.049","article-title":"Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults","volume":"25","author":"Anh","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0195","doi-asserted-by":"crossref","first-page":"e2323","DOI":"10.1371\/journal.pone.0002323","article-title":"A randomized, placebo-controlled trial of the bivalent killed, whole-cell, oral cholera vaccine in adults and children in a cholera endemic area in Kolkata, India","volume":"3","author":"Mahalanabis","year":"2008","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.12.011_b0200","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/S0140-6736(09)61297-6","article-title":"Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial","volume":"374","author":"Sur","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0205","doi-asserted-by":"crossref","first-page":"e1289","DOI":"10.1371\/journal.pntd.0001289","article-title":"Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial","volume":"5","author":"Sur","year":"2011","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0210","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S1473-3099(13)70273-1","article-title":"5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial","volume":"13","author":"Bhattacharya","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0215","doi-asserted-by":"crossref","first-page":"e0003574","DOI":"10.1371\/journal.pntd.0003574","article-title":"Flexibility of oral cholera vaccine dosing-a randomized controlled trial measuring immune responses following alternative vaccination schedules in a cholera hyper-endemic zone","volume":"9","author":"Kanungo","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0220","doi-asserted-by":"crossref","first-page":"e2828","DOI":"10.1371\/journal.pntd.0002828","article-title":"Immunogenicity of a killed bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol, in Haiti","volume":"8","author":"Charles","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0225","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.vaccine.2016.02.020","article-title":"The oral cholera vaccine Shanchol when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants","volume":"34","author":"Saha","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0230","doi-asserted-by":"crossref","first-page":"494","DOI":"10.3346\/jkms.2014.29.4.494","article-title":"Safety and immunogenicity assessment of an oral cholera vaccine through phase I clinical trial in Korea","volume":"29","author":"Baik","year":"2014","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2019.12.011_b0235","doi-asserted-by":"crossref","first-page":"6360","DOI":"10.1016\/j.vaccine.2015.08.075","article-title":"A randomized, non-inferiority trial comparing two bivalent killed, whole cell, oral cholera vaccines (Euvichol vs Shanchol) in the Philippines","volume":"33","author":"Baik","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0240","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.vaccine.2018.09.026","article-title":"The Euvichol story \u2013 Development and licensure of a safe, effective and affordable oral cholera vaccine through global public private partnerships","volume":"36","author":"Odevall","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0245","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2051013614537819","article-title":"Killed oral cholera vaccines: history, development and implementation challenges","volume":"2","author":"Lopez","year":"2014","journal-title":"Ther Adv Vaccines"},{"key":"10.1016\/j.vaccine.2019.12.011_b0250","first-page":"330","article-title":"[Community trial for safety and immunogenicity of oral-administered lyophilized rBS-WC cholera vaccine]","volume":"30","author":"Chen","year":"1996","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"10.1016\/j.vaccine.2019.12.011_b0255","first-page":"329","article-title":"The study of safety and immunogenicity in humans by oral killed whole-cell\/recombinant B-subunit cholera vaccine of capsule","author":"Xiong","year":"1998","journal-title":"J First Military Med Univ"},{"key":"10.1016\/j.vaccine.2019.12.011_b0260","first-page":"417","article-title":"Field trial of oral cholera vaccines in Bangladesh","volume":"19","author":"Clemens","year":"1988","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"10.1016\/j.vaccine.2019.12.011_b0265","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0140-6736(05)66550-6","article-title":"Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis","volume":"366","author":"Ali","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0270","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1473-3099(12)70196-2","article-title":"Effectiveness of an oral cholera vaccine in Zanzibar: findings from a mass vaccination campaign and observational cohort study","volume":"12","author":"Khatib","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0275","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1093\/cid\/cit009","article-title":"Herd protection by a bivalent killed whole-cell oral cholera vaccine in the slums of Kolkata, India","volume":"56","author":"Ali","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0280","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/S0140-6736(86)91944-6","article-title":"Field trial of oral cholera vaccines in Bangladesh","volume":"2","author":"Clemens","year":"1986","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0285","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1371\/journal.pmed.0040336","article-title":"Controlling endemic cholera with oral vaccines","volume":"4","author":"Longini","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.12.011_b0290","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrgastro.2011.174","article-title":"New-generation vaccines against cholera","volume":"8","author":"Clemens","year":"2011","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.vaccine.2019.12.011_b0295","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/infdis\/153.6.1108","article-title":"Cell Transport of Vibrio cholerae from the Intestinal. Lumen into Peyer's Patches: a mechanism for antigen sampling and for microbial transepithelial migration","volume":"153","author":"Owen","year":"1986","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0300","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1073\/pnas.76.4.2052","article-title":"Selection and characteristics of a Vibrio cholerae mutant lacking the A (ADP-ribosylating) portion of the cholera enterotoxin","volume":"76","author":"Honda","year":"1979","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2019.12.011_b0305","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/306551a0","article-title":"Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development","volume":"306","author":"Mekalanos","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2019.12.011_b0310","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(88)90120-1","article-title":"Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR","volume":"2","author":"Levine","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0315","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14760584.2017.1291348","article-title":"PaxVax CVD 103-HgR single-dose live oral cholera vaccine","volume":"16","author":"Levine","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.12.011_b0320","article-title":"An overview of Vaxchora\u2122, a live attenuated oral cholera vaccine","author":"Saluja","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.12.011_b0325","doi-asserted-by":"crossref","first-page":"e0007417","DOI":"10.1371\/journal.pntd.0007417","article-title":"Oral immunization with a probiotic cholera vaccine induces broad protective immunity against vibrio cholerae colonization and disease in mice","volume":"13","author":"Sit","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"issue":"445","key":"10.1016\/j.vaccine.2019.12.011_b0330","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aap8423","article-title":"A live vaccine rapidly protects against cholera in an infant rabbit model","volume":"10","author":"Hubbard","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.vaccine.2019.12.011_b0335","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/CVI.00601-13","article-title":"Safety and immunogenicity of single-dose live oral cholera vaccine strain CVD 103-HgR, prepared from new master and working cell banks","volume":"21","author":"Chen","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.12.011_b0340","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciw145","article-title":"Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor","volume":"62","author":"Chen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0345","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1586\/14760584.5.4.483","article-title":"Live attenuated oral cholera vaccines","volume":"5","author":"Ryan","year":"2006","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.12.011_b0350","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/0140-6736(92)92231-4","article-title":"Safety and immunogenicity of single-dose live oral cholera vaccine CVD 103-HgR in 5-9-year-old Indonesian children","volume":"340","author":"Suharyono","year":"1992","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0355","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1016\/j.vaccine.2003.11.070","article-title":"Can oral cholera vaccination play a role in controlling a cholera outbreak?","volume":"22","author":"Calain","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0360","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.ebiom.2015.09.036","article-title":"Environmental enteropathy, oral vaccine failure and growth faltering in infants in Bangladesh","volume":"2","author":"Naylor","year":"2015","journal-title":"EBioMedicine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0365","unstructured":"World Health Organization. Guidelines for the production and control of inactivated oral cholera vaccines. Series No. 924, Annex 3, ed. Geneva, 2004. p. 9\u2013149."},{"key":"10.1016\/j.vaccine.2019.12.011_b0370","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/j.1365-3083.1977.tb00376.x","article-title":"Boosting of secretory IgA antibody responses in man by parenteral cholera vaccination","volume":"6","author":"Svennerholm","year":"1977","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.vaccine.2019.12.011_b0375","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1128\/CVI.00214-16","article-title":"Parenteral vaccination can be an effective means of inducing protective mucosal responses","volume":"23","author":"Clements","year":"2016","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2019.12.011_b0380","first-page":"441","article-title":"Amniotic fluid electrolytes, urea and creatinine in normal pregnancy and cholera during pregnancy","volume":"39","author":"Ogunbode","year":"1972","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2019.12.011_b0385","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0020-7292(81)90025-4","article-title":"The significance of cholera outbreak in the prognosis of pregnancy","volume":"19","author":"Ayangade","year":"1981","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.vaccine.2019.12.011_b0390","doi-asserted-by":"crossref","first-page":"e2368","DOI":"10.1371\/journal.pntd.0002368","article-title":"Cholera in pregnancy: outcomes from a specialized cholera treatment unit for pregnant women in Leogane, Haiti","volume":"7","author":"Ciglenecki","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0395","first-page":"138","article-title":"Asiatic cholera in pregnancy","volume":"51","author":"Khan","year":"1969","journal-title":"Int Surg"},{"key":"10.1016\/j.vaccine.2019.12.011_b0400","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.medmal.2007.05.010","article-title":"Cholera and pregnancy: epidemiological, clinical, and evolutionary aspects","volume":"37","author":"Diop","year":"2007","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.vaccine.2019.12.011_b0405","doi-asserted-by":"crossref","first-page":"e1743","DOI":"10.1371\/journal.pntd.0001743","article-title":"Safety of the recombinant cholera toxin B subunit, killed whole-cell (rBS-WC) oral cholera vaccine in pregnancy","volume":"6","author":"Hashim","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0410","doi-asserted-by":"crossref","first-page":"e0004274","DOI":"10.1371\/journal.pntd.0004274","article-title":"Pregnancy outcomes after a mass vaccination campaign with an oral cholera vaccine in guinea: a retrospective cohort study","volume":"9","author":"Grout","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0415","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S1473-3099(16)30523-0","article-title":"Safety of a killed oral cholera vaccine (Shanchol) in pregnant women in Malawi: an observational cohort study","volume":"17","author":"Ali","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0420","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.vaccine.2017.01.080","article-title":"Safety of the oral cholera vaccine in pregnancy: Retrospective findings from a subgroup following mass vaccination campaign in Dhaka, Bangladesh","volume":"35","author":"Khan","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0425","doi-asserted-by":"crossref","unstructured":"WHO position paper \u2013 August 2017. Wkly Epidemiol Rec. 2017; 92: 477\u2013500.","DOI":"10.1002\/9781405166584.ch20"},{"key":"10.1016\/j.vaccine.2019.12.011_b0430","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa1312680","article-title":"Use of Vibrio cholerae vaccine in an outbreak in Guinea","volume":"370","author":"Luquero","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.011_b0435","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1016\/S2214-109X(15)70015-X","article-title":"Effectiveness of oral cholera vaccine in Haiti","volume":"3","author":"Luquero","year":"2015","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2019.12.011_b0440","series-title":"An Investment Case for the Accelerated Introduction of Oral Cholera Vaccines","author":"Levin","year":"2012"},{"key":"10.1016\/j.vaccine.2019.12.011_b0445","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.vaccine.2016.02.020","article-title":"The oral cholera vaccine Shanchol\u2122 when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants","volume":"34","author":"Saha","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0450","unstructured":"World Health Organization. WHO prequalified vaccines. Cholera: inactivated oral Shanchol, Cholera: inactivated oral Euvichol and Cholera: inactivated oral Euvichol Plus, 2019 https:\/\/extranet.who.int\/gavi\/PQ_Web\/Browse.aspx?nav=3. Accessed 28 July 2019."},{"key":"10.1016\/j.vaccine.2019.12.011_b0455","doi-asserted-by":"crossref","first-page":"e108521","DOI":"10.1371\/journal.pone.0108521","article-title":"Development of stable Vibrio cholerae O1 Hikojima type vaccine strains co-expressing the Inaba and Ogawa lipopolysaccharide antigens","volume":"9","author":"Karlsson","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.12.011_b0460","unstructured":"Chowdhury F, Syed K, Singh A, Akther A, Rahman T, Kanchan V, et al. Study to evaluate safety, tolerability and immunogenicity of two formulations of inactivated (Hikojima serotype) novel Oral Cholera Vaccine, Hillchol\u2122. United States \u2013 Japan Cooperative Medical Sciences Program. Seoul. S. Korea, 9-10 February 2017, Session 36."},{"key":"10.1016\/j.vaccine.2019.12.011_b0465","doi-asserted-by":"crossref","first-page":"6887","DOI":"10.1016\/j.vaccine.2009.09.008","article-title":"Immune responses following one and two doses of the reformulated, bivalent, killed, whole-cell, oral cholera vaccine among adults and children in Kolkata, India: a randomized, placebo-controlled trial","volume":"27","author":"Kanungo","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0470","doi-asserted-by":"crossref","first-page":"8285","DOI":"10.1016\/j.vaccine.2011.08.108","article-title":"Safety and immunogenicity study of a killed bivalent (O1 and O139) whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age","volume":"29","author":"Saha","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0475","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1510330","article-title":"Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh","volume":"374","author":"Qadri","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.011_b0480","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJMc1711583","article-title":"Single-dose cholera vaccine in response to an outbreak in Zambia","volume":"378","author":"Ferreras","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2019.12.011_b0485","doi-asserted-by":"crossref","first-page":"e1001867","DOI":"10.1371\/journal.pmed.1001867","article-title":"The impact of a one-dose versus two-dose oral cholera vaccine regimen in outbreak settings: a modeling study","volume":"12","author":"Azman","year":"2015","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2019.12.011_b0490","doi-asserted-by":"crossref","first-page":"35742","DOI":"10.1038\/srep35742","article-title":"Immune responses to an oral cholera vaccine in internally displaced persons in South Sudan","volume":"6","author":"Iyer","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2019.12.011_b0495","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1371\/journal.pntd.0000173","article-title":"The high burden of cholera in children: comparison of incidence from endemic areas in Asia and Africa","volume":"2","author":"Deen","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0500","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0264-410X(93)90019-T","article-title":"Live oral vaccines against cholera: an update","volume":"11","author":"Levine","year":"1993","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0505","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1086\/514025","article-title":"Evaluation of Peru-15, a new live oral vaccine for cholera, in volunteers","volume":"176","author":"Sack","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0510","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.mam.2011.11.001","article-title":"Vitamin A and immune regulation: role of retinoic acid in gut-associated dendritic cell education, immune protection and tolerance","volume":"33","author":"Cassani","year":"2012","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.vaccine.2019.12.011_b0515","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1017\/S0950268806007175","article-title":"Epidemic influenza and vitamin D","volume":"134","author":"Cannell","year":"2006","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2019.12.011_b0520","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1086\/368132","article-title":"Supplementation with zinc, but not vitamin A, improves seroconversion to vibriocidal antibody in children given an oral cholera vaccine","volume":"187","author":"Albert","year":"2003","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.12.011_b0525","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.vaccine.2003.07.005","article-title":"Suppressive effect of zinc on antibody response to cholera toxin in children given the killed, B subunit-whole cell, oral cholera vaccine","volume":"22","author":"Qadri","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0530","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.vaccine.2008.12.036","article-title":"Enhanced immunogenicity of an oral inactivated cholera vaccine in infants in Bangladesh obtained by zinc supplementation and by temporary withholding breast-feeding","volume":"27","author":"Ahmed","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0535","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1586\/eri.12.23","article-title":"Immune responses to cholera in children","volume":"10","author":"Leung","year":"2012","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.vaccine.2019.12.011_b0540","unstructured":"World Health Organization. WHO technical working group on creation of an oral cholera vaccine stockpile: meeting report, Geneva, 26-27 April 2012."},{"key":"10.1016\/j.vaccine.2019.12.011_b0545","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1016\/S2214-109X(16)00037-1","article-title":"A second affordable oral cholera vaccine: implications for the global vaccine stockpile","volume":"4","author":"Desai","year":"2016","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.vaccine.2019.12.011_b0550","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/21645515.2016.1245250","article-title":"Achievements and challenges for the use of killed oral cholera vaccines in the global stockpile era","volume":"13","author":"Desai","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.12.011_b0555","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2471\/BLT.14.139949","article-title":"Post-licensure deployment of oral cholera vaccines: a systematic review","volume":"92","author":"Martin","year":"2014","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2019.12.011_b0560","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1128\/IAI.73.5.3018-3024.2005","article-title":"The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers","volume":"73","author":"Garcia","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2019.12.011_b0565","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1016\/j.vaccine.2009.08.042","article-title":"Randomized, double-blind, placebo-controlled trial to evaluate the safety and immunogenicity of live oral cholera vaccine 638 in Cuban adults","volume":"27","author":"Valera","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.12.011_b0570","doi-asserted-by":"crossref","first-page":"e99381","DOI":"10.1371\/journal.pone.0099381","article-title":"Safety and immunogenicity of a live oral recombinant cholera vaccine VA1. 4: a randomized, placebo controlled trial in healthy adults in a cholera endemic area in Kolkata, India","volume":"9","author":"Kanungo","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.12.011_b0575","doi-asserted-by":"crossref","first-page":"4850","DOI":"10.1016\/j.vaccine.2009.05.065","article-title":"Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response","volume":"27","author":"Mahalanabis","year":"2009","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316536?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19316536?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:38:07Z","timestamp":1759401487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19316536"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":115,"alternative-id":["S0264410X19316536"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.011","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current and future cholera vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}